Form 4: Zura Bio Director Daniel Becker Granted 51,000 Stock Options

Zura Bio Ltd. Director Daniel J. Becker was granted 51,000 share options with an exercise price of $1.02, vesting over one year.

Summary

• Daniel J. Becker, a Director of Zura Bio Ltd. (ZURA), was granted 51,000 share options.
• The options have an exercise price of $1.02 per share.
• The grant date for these options was May 29, 2025.
• The options will vest in twelve substantially equal monthly installments over a one-year period, commencing from May 21, 2025.
• Any unvested portion will vest immediately before the next annual shareholders' meeting following the grant date, contingent on Mr. Becker's continued service.
• The options have an expiration date of May 29, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive sign of alignment between management and shareholder interests, providing an incentive for long-term value creation. It's a standard compensation practice, indicating stability in governance.

Positives

• Aligns the interests of Director Daniel J. Becker with those of shareholders through equity ownership.
• Provides an incentive for Mr. Becker to contribute to the long-term growth and success of Zura Bio Ltd.
• Standard practice for compensating directors and executives, indicating a structured compensation plan.

Negatives

• Potential for future dilution if the options are exercised, increasing the number of outstanding shares.

Risks

• The value of the options is dependent on the future market price of Zura Bio Ltd. Class A Ordinary Shares exceeding the $1.02 exercise price.
• Vesting is contingent on Daniel J. Becker's continued service as a director, meaning unvested options could be forfeited upon departure.

Future Outlook

The granted options are designed to incentivize long-term commitment and performance, with vesting tied to continued service over a one-year period from May 21, 2025, and full vesting prior to the next annual shareholder meeting.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and broader corporate sectors. It serves as a key component of executive and director compensation packages, aiming to align the interests of leadership with shareholder value creation by providing a direct financial stake in the company's performance.

Comparison to Industry Standards

• The grant of 51,000 options to a director is within the typical range for early-stage biotechnology companies, where equity compensation is often a significant part of the overall remuneration package due to limited cash flow and the high-risk, high-reward nature of the industry.
• The exercise price of $1.02, likely at or above the market price on the grant date, is standard for incentive stock options, ensuring that the director benefits only if the company's stock price appreciates.
• A one-year monthly vesting schedule is relatively short compared to typical 3-4 year vesting periods for employee stock options, but can be common for director grants, especially when combined with an accelerated vesting clause tied to the next annual meeting, reflecting the nature of board service.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also aligns director's interests with shareholder value creation.
• Employees: No direct impact mentioned, but standard compensation practices can influence overall company culture and morale.
• Management: Strengthens the incentive structure for the director to contribute to company performance.

Next Steps

• Continued service of Daniel J. Becker as a Director of Zura Bio Ltd. to ensure vesting of the options.
• Future annual meetings of shareholders, which will trigger accelerated vesting of any remaining unvested options.

Key Dates

Recommendation

Keywords

Zura Bio Ltd, ZURA, SEC Form 4, Stock Options, Director Compensation, Equity Grant, Daniel J. Becker, Beneficial Ownership, Executive Compensation, Biotechnology